© 2020 MJH Life Sciences™ and Cancer Network. All rights reserved.
Caron A. Jacobson, MD | Authors
Articles
Caron A. Jacobson, MD, on Next Steps for the Phase 2 ZUMA-5 Study
August 02, 2020
Interim results from the study suggested that axicabtagene ciloleucel (axi-cel) demonstrated significant and durable clinical benefit in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Caron A. Jacobson, MD, on What Patients Should Know About the Phase 2 ZUMA-5 Study
July 14, 2020
The expert in hematology discussed what patients should know about the study, which evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Phase 2 ZUMA-5 Study Results Show Promise for Axi-Cel in Indolent Non-Hodgkin Lymphoma
June 27, 2020
Results from the phase 2 ZUMA-5 study indicated that axicabtagene ciloleucel (axi-cel) may be a promising approach for treating this patient population.
Caron A. Jacobson, MD, on the Findings of the Phase 2 ZUMA-5 Study
June 14, 2020
The study assessed the use of axicabtagene ciloleucel in patients with relapsed or refractory indolent non-Hodgkin lymphoma.